<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035515</url>
  </required_header>
  <id_info>
    <org_study_id>204HV102</org_study_id>
    <nct_id>NCT01035515</nct_id>
  </id_info>
  <brief_title>BIIB014 Cardiovascular Monitoring Study</brief_title>
  <official_title>A Single-Center, Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Cardiovascular Effects of Single Doses of Oral BIIB014 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine the effects of a single dose of BIIB014 on blood pressure and
      haemodynamic variables in healthy volunteers over 24 hours.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Supine Blood pressure</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm One</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 of 6 cross-over arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Two</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 of 6 cross-over arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Three</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 3 of 6 cross-over arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Four</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 4 of 6 cross-over arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Five</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 5 of 6 cross-over arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Six</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 of 6 cross-over arms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose oral capsule placebo comparator</description>
    <arm_group_label>Arm Six</arm_group_label>
    <arm_group_label>Arm Two</arm_group_label>
    <arm_group_label>Arm Four</arm_group_label>
    <arm_group_label>Arm Three</arm_group_label>
    <arm_group_label>Arm Five</arm_group_label>
    <arm_group_label>Arm One</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB014 50mg</intervention_name>
    <description>Single dose oral capsule 50mg BIIB014</description>
    <arm_group_label>Arm Six</arm_group_label>
    <arm_group_label>Arm Two</arm_group_label>
    <arm_group_label>Arm Four</arm_group_label>
    <arm_group_label>Arm Three</arm_group_label>
    <arm_group_label>Arm Five</arm_group_label>
    <arm_group_label>Arm One</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB014 100mg</intervention_name>
    <description>Single dose oral capsule 100mg BIIB014</description>
    <arm_group_label>Arm Six</arm_group_label>
    <arm_group_label>Arm Two</arm_group_label>
    <arm_group_label>Arm Four</arm_group_label>
    <arm_group_label>Arm Three</arm_group_label>
    <arm_group_label>Arm Five</arm_group_label>
    <arm_group_label>Arm One</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects

          -  Between the ages of 18 and 50, inclusive.

          -  Must have a body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive

        Exclusion Criteria:

          -  Clinically significant abnormalities (as determined by the Investigator)

          -  Other unspecified reason that would make the subject unsuitable for enrollment (as
             determined by the Investigator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quintiles Inc</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <last_update_submitted>June 17, 2010</last_update_submitted>
  <last_update_submitted_qc>June 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec Study MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

